Alamar Biosciences, Inc. 8-K

What Happened
Alamar Biosciences, Inc. announced that it completed its initial public offering (IPO) on April 20, 2026. The company sold an aggregate of 12,937,500 shares of common stock (including full exercise of the underwriters’ 1,687,500‑share option) at $17.00 per share, generating approximately $219.9 million in aggregate gross proceeds before underwriting discounts, commissions and offering expenses. Simultaneously, Alamar filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws, effective immediately prior to the IPO closing.

Key Details

• IPO closing date: April 20, 2026.
• Shares sold: 12,937,500 common shares (includes 1,687,500 shares from full exercise of underwriters’ option).
• Public offering price: $17.00 per share.
• Aggregate gross proceeds: ~ $219.9 million (before underwriting discounts/commissions and offering expenses).
• Corporate governance updates: Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws filed/ adopted effective as of the IPO closing.

Why It Matters
Being publicly listed provides Alamar with access to public equity capital and creates liquidity for shareholders. The substantial gross proceeds strengthen the company’s balance sheet and can support its business plans (exact uses not detailed in this filing). The amended charter and bylaws reflect the company’s governance structure as a public company and may affect shareholder rights, board procedures and other corporate governance matters.